Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes

• Status: Completed
• Trial end date: 2004-01-29

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the safety and efficacy of insulin aspart produced by current process compared to that of insulin aspart produced by NN2000 process in subjects with type 2 diabetes.

• Phase: Phase 3

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Long-Acting